St. Jude Children's Research: ALL5

APPLICATIONS / DATABASES

SUPPLEMENTAL DATA

FACULTY

MIRROR SITES

COLLABORATIVE PROJECTS

DEPARTMENTS

Home > Supplemental Data > ALL5

Supplementary Information for:

Identification of genes associated with chemotherapy cross-resistance and treatment response in childhood acute lymphoblastic leukemia.

Sanne Lugthart 1,2,6,8 , Meyling H. Cheok 1,2,8 , Monique L. den Boer 6 , Wenjian Yang 1,2,5 , Amy Holleman 6 , Cheng Cheng 3 , Ching-Hon Pui 1,4,5 , Mary V. Relling 1,2,5 , Gritta E. Janka-Schaub 7 , Rob Pieters 6,9 , William E. Evans 1,2,5,9

1 Hematological Malignancy Program
2 Department of Pharmaceutical Sciences
3 Department of Biostatistics
4 Department of Hematology-Oncology ,St. Jude Children's Research Hospital , Memphis , USA
5 The Pharmacogenetics of Anticancer Agents Research Group in the Pharmacogenetics Research Network, Memphis , Tennessee , USA
6 Department of Pediatric Oncology/Hematology ,Erasmus University Medical Center/Sophia Children's Hospital, ,Rotterdam , The Netherlands
7 COALL study group ,Children's University Hospital , Hamburg , Germany
8 These first authors contributed equally to this work.
9 These last authors contributed equally to this work.

Supplemental Figure 4: Principal component analysis plot of genes discriminating cross-resistance and VCR-ASP discordant resistance.

Illustrated are the first three components of the principal component analysis (PCA) to visualize differences among ALL cells using the gene expression signatures identified. A. Expression of 51 gene probe sets that significantly discriminate cross-resistant (red; n=29) from cross-sensitive (green; n=38) B-lineage ALL patients (P<0.0001) in three-dimensional space. B. Gene expression of 200 gene probe sets (P<0.00006) that significantly discriminate VCR-resistant (VCR-R) plus ASP-sensitive (ASP-S) (orange; n=34) patients from VCR-sensitive plus ASP-resistance patients (blue; n=42) were used.